Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Consensus Recommendation of “Hold” by Brokerages

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) has been assigned an average rating of “Hold” from the six research firms that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, four have given a hold recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $5.00.

Separately, Wells Fargo & Company initiated coverage on Zentalis Pharmaceuticals in a report on Tuesday, March 17th. They issued an “equal weight” rating and a $5.00 price target on the stock.

Zentalis Pharmaceuticals Stock Performance

Shares of ZNTL stock opened at $2.55 on Thursday. The company has a market capitalization of $184.24 million, a PE ratio of -1.23 and a beta of 1.71. Zentalis Pharmaceuticals has a 52-week low of $1.01 and a 52-week high of $3.95. The business’s fifty day moving average is $2.59 and its 200 day moving average is $1.93.

Insider Activity at Zentalis Pharmaceuticals

In related news, insider Vincent Vultaggio sold 29,951 shares of the company’s stock in a transaction that occurred on Friday, February 6th. The shares were sold at an average price of $2.43, for a total value of $72,780.93. Following the transaction, the insider directly owned 156,779 shares in the company, valued at approximately $380,972.97. This represents a 16.04% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Group Walters bought 6,459,973 shares of the stock in a transaction that occurred on Wednesday, December 31st. The stock was bought at an average cost of $1.20 per share, for a total transaction of $7,751,967.60. Following the completion of the purchase, the insider directly owned 13,509,973 shares of the company’s stock, valued at $16,211,967.60. This represents a 91.63% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders sold 46,617 shares of company stock worth $113,417. 1.90% of the stock is owned by company insiders.

Institutional Trading of Zentalis Pharmaceuticals

Hedge funds have recently made changes to their positions in the stock. Sivia Capital Partners LLC bought a new stake in Zentalis Pharmaceuticals in the fourth quarter worth $27,000. Catalyst Funds Management Pty Ltd bought a new position in shares of Zentalis Pharmaceuticals during the second quarter valued at about $31,000. Voleon Capital Management LP purchased a new position in shares of Zentalis Pharmaceuticals in the third quarter worth about $41,000. SG Americas Securities LLC increased its holdings in shares of Zentalis Pharmaceuticals by 35.3% in the third quarter. SG Americas Securities LLC now owns 31,579 shares of the company’s stock worth $48,000 after buying an additional 8,236 shares during the period. Finally, Qube Research & Technologies Ltd bought a new stake in shares of Zentalis Pharmaceuticals in the 2nd quarter valued at about $37,000.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.